Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Isula Rain

This article was originally published in The Tan Sheet

Executive Summary

FDA has "significant concerns" regarding the safety of two new dietary ingredients contained in the company's "Temporal Tension Extract"; the agency's comments respond to a 75-day premarket notification filed April 11. FDA's June 29 response notes scientific information for Kalanchoe pinnata and Ruta chalepensis do not meet the requirements of the FD&C Act "because it does not contain a description of the dietary supplement that contains the new dietary ingredients including the level of the new dietary ingredients in the dietary supplement...nor does it describe, in any quantitative manner, the amount to be consumed daily." The letter to the Larkspur, Calif.-based company goes on to say that history of use information provided fails to adequately establish safety
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS091488

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel